Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue

European Journal of Cancer

Volumn 36, Issue 9, 2000, Pages 1161-1170

  Tahir, S K ^a   Gu, W Z ^a   Zhang, H C ^a   Leal, J ^a   Lee, J Y ^a   Kovar, P ^a   Saeed, B ^a   Cherian, S P ^a   Devine, E ^a   Cohen, J ^a   Warner, R ^a   Wang, Y C ^a   Stout, D ^a   Arendsen, D L ^a   Rosenberg, S ^a   Ng, S C ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Angiogenesis; Cyclophosphamide; Farnesyl pyrophosphate analogue; Farnesyltransferase; Human tumour xenograft; Ras processing; Squalene synthase; Vascular endothelial growth factor

Indexed keywords

A 176120; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; SQUALENE SYNTHASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL DIVISION; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; LYMPHOKINES; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; POLYISOPRENYL PHOSPHATES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034070276     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00067-8     Document Type: Article

References (36)

1. Hancock J.F. Anti-Ras drugs come of age. Current Biol. 3:1993;770-772.
2. Newman C.M.H., Magee A.I. Posttranslational processing of the ras superfamily of small GTP-binding proteins. Biochim. Biophys. Acta. 1155:1993;79-96.
3. Bollag G., McCormick F. Regulators and effectors of ras proteins. Annu. Rev. Cell. Biol. 7:1991;601-632.
4. Lowy D.R., Willumsen B.M. Function and regulation of ras. Annu. Rev. Biochem. 62:1993;851-891.
5. Bos J.L. ras Oncogenes in human cancer. a review Cancer Res. 49:1989;4682-4689.
6. Kiaris H., Spandidos D. Mutations of ras genes in human tumors. Int. J. Oncol. 7:1995;413-421.
7. Boguski M.S., McCormick F. Proteins regulating Ras and its relatives. Nature. 366:1993;643-654.
8. Quilliam L.A., Khosravi-Far R., Huff S.Y., Der C.J. Guanine nucleotide exchange factors. activators of the Ras superfamily of proteins BioEssays. 17:1995;395-404.
9. Barbacid M. Ras genes. Annu. Rev. Biochem. 56:1987;779-827.
10. Hamilton A.D., Sebti S.M. Inhibitors of Ras farnesyltransferase as novel antitumor agents. DN&P. 8:1995;138-145.
11. Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase inhibitors. Ras research yields a potential cancer therapeutic Cell. 77:1994;175-178.
12. Qian Y., Sebti S.M., Hamilton A.D. Farnesyltransferase as a target for anticancer drug design. Biopolymers. 43:1997;25-41.
13. Lerner E.C., Hamilton A.D., Sebti S.M. Inhibition of Ras prenylation. a signaling target for novel anti-cancer drug design Anti-Cancer Drug Design. 12:1997;229-238.
14. Manne V., Ricca C.S., Brown J.G.et al. Ras farnesylation as a target for novel antitumor agents. potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase Drug Dev. Res. 34:1995;121-137.
15. Harwood Jr H.J. Protein farnesyltransferase. measurement of enzymatic activity in 96-well format using TopCount microplate scintillation counting technology Analyt. Biochem. 226:1995;268-278.
16. Agnew W.S. Squalene synthetase. Meth. Enzymol. 110:1985;359-373.
17. Gu W., Tahir S.K., Wang Y.et al. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur. J. Cancer. 35:1999;1394-1401.
18. Plowman J., Dykes D.J., Hollingshead M., Simpson-Herren L., Alley M.C. Human tumor xenograft models in NCI drug development. Teicher B. Anticancer Drug Development Guide. Preclinical Screening, Clinical Trials, and Approval:1997;101-125 Humana Press, Totowa.
19. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Sasazuki T., Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression. implications for induction and inhibition of tumor angiogenesis Cancer Res. 55:1995;4575-4580.
20. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature (Lond.). 343:1990;425-430.
21. Gibbs J.B., Pompliano D.L., Mosser S.D.et al. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J. Biol. Chem. 268:1993;7617-7620.
22. Yonemoto M., Satoh T., Arakawa H.et al. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner. Mol. Pharm. 55:1998;1-7.
23. Lebowitz P.F., Prendergast G.C. Non-Ras targets of farnesyltransferase inhibitors. focus on Rho Oncogene. 17:1998;1439-1445.
24. Du W., Lebowitz P.F., Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19:1999;1831-1840.
25. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatment. targeting simply Ras? Biochim. Biophys. Acta. 1333:1997;F51-71.
26. Johnson L., Greenbaum D., Cichowski K.et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Develop. 11:1997;2468-2481.
27. Fox P.L., Sa G., Dobrowolski S.F. The regulation of endothelial cell motility by p21 ras. Oncogene. 9:1994;3519-3526.
28. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metast. Rev. 14:1995;263-277.
29. Okada F., Rak J.W., Croix B.S.et al. Impact of oncogenes in tumor angiogenesis. mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells Proc. Natl. Acad. Sci. (Wash.). 95:1998;3609-3614.
30. Ingber DE, Prusty D, Sun Z, Betensky H, Wang N. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis. J Biomech 1995, 1471-1484.
31. Prendergast G.C., Davide J.P., DeSolms S.J.et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 14:1994;4193-4202.
32. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factors act as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 1:1995;1024-1028.
33. Criscuolo G.R., Balledux J.P. Clinical neurosciences in the decade of the brain. hypotheses in neuro-oncology. VEG/PF acts upon the actin cytoskeleton and is inhibited by dexamethasone: relevance to tumor angiogenesis and vasogenic edema Yale J. Biol. Med. 69:1996;337-355.
34. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:1999;159-165.
35. Prendergast G.C., Davide J.P., Lebowitz P.F., Weshsler-Reya R., Kohl N.E. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res. 56:1996;2626-2632.
36. Kerbel R.S. A cancer therapy resistant to resistance. Nature. 390:1997;335-336.